Stanford V chemotherapy and limited filed irradiation for patients with unfavorable risk stage I-II classic Hodgkin lymphoma

This study aimed to investigate the long-term outcomes for patients with stage I-II classic Hodgkin lymphoma and unfavorable risk who were treated with Stanford V combined modality therapy. 

This study concluded that the long-term outcomes for these patients were favorable and comparable to other standard treatments.  

Standard treatments for stage I-II unfavorable risk Hodgkin lymphoma (HL) include ABVD or BEACOPP. ABVD is a chemotherapy first-line treatment for HL. It involves treatment with doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban), and dacarbazine (DTIC). BEACOPP is another chemotherapy-based treatment. It involves bleomycin, etoposide (Etopophos), doxorubicin, cyclophosphamide (Cytoxan), vincristine (Oncovin), procarbazine (Matulane) and prednisolone (Deltasone).  

Standford V is a chemotherapy regimen consisting of mechlorethamine (Mustargen), doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and prednisone. It contains lower doses of doxorubicin and bleomycin than the ABVD and BEACOPP regimes. Stanford V combined modality therapy (CMT) pairs chemotherapy and radiotherapy. 

It was unknown if Stanford V CMT had favorable long-term outcomes for stage I-II unfavorable risk HL patients.  

This study involved 168 patients with stage I-II unfavorable risk HL. Patients were treated with 8-12 weeks of Stanford V CMT and consolidative radiotherapy. Patients were followed for an average of 8.4 years.  

The 10-year overall survival (OS) rate was 95%. The 10-year progression-free survival (PFS) rate was 88%. 18 relapses occurred and 13 of these were salvaged successfully.  

There were no cases of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after primary therapy. MDS is a rare type of blood cancer. 

This study concluded that the long-term outcomes of stage I–II unfavorable risk HL treated with Stanford V CMT are comparable to ABVD or BEACOPP regimens. 

This study was based on medical records. Information might have been missing. Also, the follow-up period varied among patients.